Date:	8/5/2022	
Your Name:	Emilie L. Castranio	
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease	
Manuscript Number (if known):	ADJ-D-22-00447	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	P30AG066514 to Mary Sano with Developmental Pilot Award  Time frame: past 36 months	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None □	

			Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	■ None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠  None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠     None	
13	Other financial or non-financial interests	None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date	e:	<del>-</del>	8/3/2022		
Your Name:  Manuscript Title:		<del>-</del>	Philip Hasel		
		_	Microglial INPP5D limits plaque formation a Alzheimer's disease	and glial reactivity in the PSAPP mouse model of	
Mar	uscript Number (if k	nown): _	ADJ-D-22-00447		
cont affe	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				
epid		nsion, you		example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.		vithout time limit. For all other items, the time			
			entities with whom you have this nip or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	)
			<del>-</del>	made to you or to your institution)	9
	All support for the		nip or indicate none (add rows as needed)  Time frame: Since the initial planning	made to you or to your institution)	9
	All support for the present manuscript (e.g., funding, provision	relationsl	nip or indicate none (add rows as needed)  Time frame: Since the initial planning	made to you or to your institution)	
	All support for the present manuscript (e.g.,	relationsl	Time frame: Since the initial planning ne degenerative Diseases Consortium	made to you or to your institution) of the work	
	All support for the present manuscript (e.g., funding, provision of study materials,	relationsl	Time frame: Since the initial planning ne degenerative Diseases Consortium	made to you or to your institution)  of the work  Institution	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for	relationsl	Time frame: Since the initial planning ne degenerative Diseases Consortium	made to you or to your institution)  of the work  Institution  Click the tab key to add additional rows.	

Royalties or

licenses

**⊠** None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠  None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠     None	
13	Other financial or non-financial interests	⊠  None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/3/2021
Your Name:	Jean-Vianney Haure-Mirande
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-22-00447
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	
The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	National Institute on Aging - R03AG070710	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	⊠  None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠]   None	
13	Other financial or non-financial interests	⊠  None	
Plea 🖂	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	8/3/2021
Your Name:	Angie V Ramirez Jimenez
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-22-00447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	8/3/2022
Your Name:	Bradley Wade Hamilton
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-22-00447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None  Time frame: past	Click the tab key to add additional rows.  6 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	8/3/2022
Your Name:	Rachel D. Kim
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of
	Alzheimer's disease
Manuscript Number (if known):	ADJ-D-22-00447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	8/5/2022
Your Name:	Charles Glabe
Manuscript Title:	[Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-22-00447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	[⊠] None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	[⊠] None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
13	Other financial or non-financial interests	[⊠] None			
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:		8/3/2021			
Your Name:		Minghui Wang	Minghui Wang		
Mar	nuscript Title:		Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease		
Mar	nuscript Number (if kı	own): ADJ-D-22-00447			
cont affe	tent of your manuscri cted by the content o	t. "Related" means any ro the manuscript. Disclosu	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
epid	lemiology of hyperten		ll relationships with manuf	example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report ane for disclosure is the		ported in this manuscript w	ithout time limit. For all other items, the time	
		Name all entities with who	om you have this one (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time fram	e: Since the initial planning	of the work	
	All support for the	Time fram	e: Since the initial planning	of the work	
	present manuscript (e.g.,	f 1		of the work	
	present manuscript (e.g., funding, provision	□ None			
	present manuscript (e.g.,	□ None		of the work  Click the tab key to add additional rows.	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	□ None  NIH/NIA Grant U01 AG0		Click the tab key to add additional rows.	

Royalties or

licenses

**⊠** None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	■ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None			
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:			8/3/2021		
Your Name:			Bin Zhang		
Manuscript Title:			Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease		
Mar	nuscript Number (if k	known):	ADJ-D-22-00447		
content of your manuscript. "Relaffected by the content of the maindicate a bias. If you are in doub."  The author's relationships/activitie epidemiology of hypertension, you		ript. "Rela of the ma e in doub os/activitions, you	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be inuscript. Disclosure represents a commitment to transparency and does not necessarily at about whether to list a relationship/activity/interest, it is preferable that you do so.  ies/interests should be defined broadly. For example, if your manuscript pertains to the bu should declare all relationships with manufacturers of antihypertensive medication, even if		
In item #1 below, report all support frame for disclosure is the past 36		: all suppo	rt for the work reported in this manuscript w	ithout time limit. For all other items, the time	
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	[ <del></del> ]	A Grant U01 AG046170	Click the tab key to add additional rows.	
			Time frame: past 36 month:	s	
2	Grants or contracts from any entity (if not indicated in item #1 above).		one		
3	Royalties or licenses	⊠ No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None     Non	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None   PCT/US21/56310   PCT/US21/56315	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Editorial Board of Molecular Neurodegeneration	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	[⊠] None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠  None			
13	Other financial or non-financial interests	None			
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.				

Date:	8/3/2022			
Your Name:	Sam Gandy MD PhD			
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease			
Manuscript Number (if known):	ADJ-D-22-00447			
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub The author's relationships/activiti epidemiology of hypertension, yo that medication is not mentioned	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.  The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.  In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time			

Name all entities with whom you have this Specifications/Comments (e.g., if payments were made to you or to your institution) relationship or indicate none (add rows as needed) Time frame: Since the initial planning of the work All support for the □ None present manuscript (e.g., U01AG046170, funding, provision RF1AG058469, of study materials, RF1AG059319, medical writing, R01AG061894 article processing P30AG066514 to Mary Sano. charges, etc.) Cure Alzheimer's Fund No time limit for Click the tab key to add additional rows this item. Time frame: past 36 months Grants or None contracts from any entity (if not Dr Gandy receives research support from the indicated in item NIH (listed above) #1 above). Royalties or  $\boxtimes$ 3 None licenses

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
			Dr. Gandy serves as a consultant for Ritrova Therapeutics and as a founder of a Recuerdo Pharmaceuticals (inactive).
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	Dr. Gandy has received compensation for chart review in connection with medical litigation in the area of cognitive function
7	Support for attending meetings and/or travel	Diabetes and Brain imaging, Kuwait City, ~2019	
8	Patents planned, issued or pending	CSF phosphoprotein assay for neurological diagnosis, 1988 iPSC protocol for generation of basal forebrain cholinergic neurons, 2020	
9	Participation on a Data Safety Monitoring Board or Advisory Board	NYU Department of Psychiatry and Pathology Abeta dynamics in escitalopram treatment of MDD, 2021-present	
10	Leadership or fiduciary role in other board, society, committee or	Medical and Scientific Advisory Council, Alzheimer's Association, 1990-1999	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	advocacy group, paid or unpaid	MASB, Alzheimer's Disease International, currently			
11	Stock or stock options	Recuerdo Therapeutics (inactive)			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Grateful patient gift account, ISMMS			
13	Other financial or non-financial interests	None			
Plea	Please place an "X" next to the following statement to indicate your agreement:				

Date:	8/5/2022
Your Name:	Shane Antony Liddelow
Manuscript Title:	Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease
Manuscript Number (if known):	ADJ-D-22-00447

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
	All support for the present	□ None			
	manuscript (e.g.,	NIH/NEI R01EY033353	Institution		
	funding, provision	NYU Grossman School of Medicine	Institution		
	of study materials,	the Blas Frangione Foundation	Institution		
	medical writing, article processing	the Gifford Family Neuroimmune Consortium as part of the Cure Alzheimer's Fund	Institution		
	charges, etc.)	Private donors: anonymous, Paul Slavik	Institution		
	No time limit for this item.	the Neurodegenerative Diseases Consortium from MD Anderson	Institution		
		Alzheimer's Research UK	Institution		
		The Alzheimer's Association	Institution		
		the Alzheimer's Disease Resource Center at NYU Langone Medical Center	institution		
		Time frame: past 36 month	ns		
2	Grants or contracts from	□ None			
	any entity (if not	Parekh Center for Interdisciplinary Neurology	Institution		
	indicated in item	Wings for Life	Institution		
	#1 above).	Melanoma Research Alliance	Institution		
		Mass General Hospital	Institution		
		National Multiple Sclerosis Society	Institution		
		American Cancer Society	institution		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None None	
4	Consulting fees	None  10x Genomics (past)  Merck (past)  Nextcure (past)	Personal Personal
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None  06/05/22 Invited speaker, Institute of Molecular Medicine (iMM), Lisbon, Portugal.  05/19/22 Invited speaker, Neuroscience Seminar Series, Case Western Reserve University School of Medicine, OH.  04/03/22 Keynote speaker, IV Neurobiology meeting from the Mexican Society for Biochemistry (Cartel IV Congreso Neurobiologica 2022), Oaxaca City, Mexico. (also Keynote speaker for pre-meeting 'Organoids and single-cell sequencing in Neuroscience"  08/15/22 Invited speaker, UC Irvine Center for Neural Circuit Mapping Conference: Linking Brain Function to Cell Types and Circuits, UCI, Irvine, CA.  06/07/22 Invited speaker, Invited speaker, Biannual Fresco Parkinson Institute Symposium, Florence, Italy.	Personal (travel and lodging)  Personal (travel and lodging)  Personal (travel and lodging)  Personal (travel and lodging)  Personal (travel and lodging)

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		11/21/19 Invited speaker, Cell and Molecular Biology seminar series, Duke University, Durham, NC.	Personal (travel and lodging)
		11/07/19 Invited speaker, workshop leader, Louis J Fox Center for Vision Restoration/Glaucoma Research Foundation joint workshop, Miami, FL.	Personal (travel and lodging)
		10/31/19 Invited speaker, The Jackson Laboratory, Bar Harbor, ME.	Personal (travel and lodging)
		09/05/19 Invited speaker, Karolinska Institute, Developing Brains symposium, Stockholm, Sweden.	Personal (travel and lodging)
		08/19/19 Invited speaker, Amgen, Cambridge, MS.	Personal (travel and lodging)
		07/21/19 Invited speaker, GRC on Amyotrophic Later Sclerosis (ALS) & Related Motor Neuron Diseases, Mount Snow, VT.	Personal (travel and lodging)
8	Patents planned, issued or	□ None	
	pending	WO2018081250A1 Liddelow SA, Guttenplan KA, Barres BA. NEURONAL AND OLIGODENDROCYTE SURVIVAL MODULATION.	
		147462.002280. Guttenplan KA, Barres BA, Liddelow SA. METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL.	
9	Participation on a Data Safety	[⊠] None	
	Monitoring Board or	Scientific Advisory Board, RM Global BioAccess Fund	
	Advisory Board	Scientific Advisory Board, Catalyst for a Cure 4 (Glaucoma Research Fund)	
		Scientific Advisory Board, Genome Technology Center, NYU Grossman School of Medicine	
10	Leadership or fiduciary role in	□ None	
	other board,	Editorial board, Glia	
	society, committee or	Editorial board, Cell Reports Editorial board	
	advocacy group,	2021 Program Committee, XV European Meeting	
	paid or unpaid	of Glial Cells in Health and Disease, Marseille, France.	
		2021 Scientific Program Committee, AAIC	
		Neuroscience Next (virtual)  2020 onwards Research Leadership Group, Cure	
		Alzheimer's Foundation	
11	Stock or stock options	□ None	
		AstronauTx	Personal
		RM Global	Personal

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

4 12/13/2021 ICMJE Disclosure Form

Michelle E Ehrlich MD	
Microglial INPP5D limits plaque formation and glial reactivity in the PSAPP mouse model of Alzheimer's disease	
ADJ-D-22-00447	
[	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None	Dr. Ehrlich receives research support from the NIH (listed above).
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	Dr. Ehrlich serves as an expert consultant for reviewing medicolegal cases.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	Dr. Ehrlich has received compensation for chart review in connection with medical litigation.
7	Support for attending meetings and/or travel	NIH AMP-AD meeting only. No pharm-sponsored meetings.	
8	Patents planned, issued or pending	iPSC protocol for generation of basal forebrain cholinergic neurons, 2020	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Member Dystonia Medical Research Foundation SAB	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Recuerdo Therapeutics (inactive)	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement:			
	I certify that I have answered every question and have not altered the wording of any of the questions on this form.		